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Introduction: Chronic inflammatory neuropathies are disorders caused by an immune response 
to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy 
(CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM 
monoclonal gammopathy and other less frequent neuropathies. Several immune therapies have 
been proven to be effective in these neuropathies even if the best therapeutic option is still  
unsettled. 
Areas covered: We reviewed the literature to compare the efficacy and safety of currently used 
immune therapies in these neuropathies. We also analysed the effect of other immune 
suppressive agents and of biological agents including rituximab, eculizumab, natalizumab,  
alemtuzumab and fingolimod that were found effective in other autoimmune diseases. 
Expert commentary: Despite the reported efficacy of a number of new immune therapies in 
some patients with immune mediated neuropathies, their efficacy has not been so far confirmed 
in randomized controlled studies. High-dose intravenous immunoglobulin (IVIg) (and 
subcutaneous immunoglobulin [SCIg] for maintenance treatment), steroids and plasma exchange 
remain the only therapy of proven efficacy in CIDP, IVIg in MMN and, with certain limits, 
rituximab and, occasionally plasma exchange in neuropathy associated with anti-MAG 
antibodies. New biological agents are also on the horizon but their efficacy needs to be proved in 




 Chronic inflammatory neuropathies are an heterogeneous group of disorders deemed to 
be caused by an autoimmune reaction against peripheral nerve. They mainly include chronic 
inflammatory demyelinating polyradiculoneuropathy (CIDP) and its variants, multifocal motor 
neuropathy (MMN) and neuropathy associated with an IgM monoclonal gammopathy with 
antibody activity against the myelin-associated glycoprotein (MAG). Most patients with these 
neuropathies respond to immune therapies even if their effect varies in the different forms and 
among the different variants of CIDP. We review the effect of therapies in these neuropathies 
and suggest a therapeutic approach to these neuropathies.  
 
SEARCH STRATEGY 
We performed a search of available studies up to April 2014 on  the Cochrane 
Neuromuscular Specialized Register and the Cochrane Central Register of Controlled Trials 
(CENTRAL) on the Cochrane Library and on Medline. We used the search terms steroids, 
corticosteroids, prednisone, prednisolone, methylprednisolone, dexamethasone, high dose 
intravenous immunoglobulin, IVIg, immunoglobulins, subcutaneous immunoglobulin, SCIg, 
azathioprine, methotrexate, interferon, cyclosporin, rituximab, cyclophosphamide, alentuzumab, 
mycophenolate, fingolimod, natalizumab, immune therapy, chronic inflammatory demyelinating  
polyradiculoneuropathy or polyneuropathy or polyradiculopathy, CIDP, polyneuropathy, 
neuropathy and polyneuritis. We provided our personal view on treatment strategies under the 
sections “How we treat ..” based on available guidelines and on our personal experience. 
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1. CHRONIC INFLAMMATORY DEMYELINATING 
POLYRADICULONEUROPATHY 
1.a Clinical features and Diagnosis 
 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic and 
disabling disorder of the peripheral nervous system [1, 2] with a prevalence ranging from  0.8 to 
8.9/100,000 [3-5]. CIDP may affect individuals at any age even if in most series the mean age of 
onset is around 40-50 years.  There is a general consensus that CIDP is an immune mediated 
disorder affecting peripheral nerve myelin even if the target of this immune response is rarely 
identified [6, 7]. CIDP may have a chronic progressive or a relapsing course affecting the 
sensory and motor nerves while an autonomic impairment is uncommon. A number of atypical 
variants of CIDP have been described including Lewis-Sumner syndrome (multifocal acquired 
demyelinating sensory and motor – MADSAM-  neuropathy), distal acquired demyelinating 
symmetric (DADS) neuropathy, purely motor, purely sensory and focal CIDP [2, 7]. CIDP is a 
severe disease with over 50% of the patients having a severe disability in the course of the 
disease leading to inability to walk without support and approximately 10% eventually become 
persistently disabled or die because of the illness [3]. Even if the diagnosis of CIDP is often easy 
in the clinical practice, the use of expensive therapies for this disease and the description of a few 
variants has led to the proposal of at least 15 diagnostic criteria [8] to define the boundaries of 
this neuropathy. This in order to avoid the inappropriate use of therapies in patients who might 
be not affected by CIDP without excluding patients who might benefit from immune treatment. 
The recently revised criteria of the EFNS/PNS [9] have the advantage of including patients with 
typical and atypical presentation of CIDP and to include patients with a demyelinating 
abnormalities in a single nerve when other supportive criteria for the diagnosis of CIDP are 
present.  
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When CIDP is suspected based on a relapsing or progressive impairment that might not 
be as slow as usually observed in other chronic acquired neuropathy and that might also affect 
proximal strength, motor and sensory nerve conduction studies are considered to be sufficient for  
the diagnosis of CIDP [9]. When these studies do not show signs of multifocal demyelination 
with reduced conduction velocities, increased latencies and conduction block, the diagnosis of 
CIDP may be supported by cerebrospinal fluid examination showing increased proteins with 
normal cells in over 80% of the patients. Magnetic resonance imaging (MRI) and nerve 
ultrasound (US) may be also helpful by revealing gadolinium enhancement or hypertrophy of 
spinal roots, brachial or lumbosacral plexus. Sural nerve biopsy is often unnecessary in most 
patients with suspected CIDP, since the findings are neither sensitive nor specific. In addition it 
is an invasive procedure technique that should be probably considered only when other tests are 
inconclusive. In these patients nerve biopsy may occasionally identify vasculitis, amyloidosis, 
sarcoidosis, or tumor infiltration of the nerve [9].   
1.b Treatment and Management 
 Several controlled studies have shown the efficacy of steroids [10],  plasma exchange 
[11, 12], and IVIg in CIDP [13-17] with approximately 50-70% of the patients responding to 
each of these treatments. In addition almost 50% of patients not responding to one of these 
treatments respond to the second therapy used leading to an improvement in 80% of reported 
patients [18, 19]. The efficacy of these therapies was confirmed  in recent Cochrane Reviews 
[20-23], in the Guidelines of the EFNS/PNS [9], and, for IVIg, in an evidence-based guideline of 
the American Academy of Neurology [24].  
How to start treatment in CIDP: IVIg or steroids? It is often difficult for the clinician to 
decide what therapy should be first used in CIDP. This decision should consider the efficacy, 
cost and side effects of each these therapies. A few randomized trial have shown a comparable 
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short-term efficacy of IVIg and oral corticosteroids [25] and of IVIg and plasma exchange [26] 
in CIDP and more recent trials have shown that both IVIg [13] and steroids [27] have prolonged 
efficacy in CIDP. A randomized controlled trial (IMC study) comparing the efficacy of six-
month therapy with IVIg or intravenous methylprednisolone (IVMP) showed however, that IVIg 
were more frequently effective than steroids during the first six month of treatment [28]. This  
difference might have reflected however a more rapid efficacy of IVIg compared to steroids 
since patients not responding within two months to the first therapy were shifted to the 
alternative therapy.  This hypothesis is supported by the results of the PREDICT study [29] 
where the median time to improvement in patients treated with pulsed monthly oral 
dexamethasone was 17 weeks and of 39 weeks for daily oral prednisolone while in the ICE trial, 
IVIg showed to be effective in most patients within the first two months of therapy [30]. In the 
IMC study it was also shown that, when effective, steroids were less frequently associated with 
deterioration after therapy discontinuation than IVIg [28]. This data were confirmed in the 
follow-up extension of  the study [31] showing  that a similar proportion of patients eventually 
deteriorated after discontinuing IVIg (87%) or IVMP (79%) even if the median time to 
deterioration was longer after discontinuing IVMP (14 months) than IVIg (4.5 months). A 
similar difference also derives from  the PREDICT study where the median time to relapse after 
therapy discontinuation  was 17.5 months after pulsed dexamethasone and 11 months after  oral 
prednisolone [31] while in the ICE trial 45% of the patients relapsed within 6 months after 
suspending 6 months therapy with IVIg  [28]. A similar difference on the prolonged efficacy of 
the two treatment derives from a large retrospective study on 70 patients showing that the 
possibility to stop treatment tended to be more frequent in patients who responded to steroids 
than to IVIg  [32].  
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Steroid are usually well tolerated over the short term even if agitation and hyperglycemia 
may early occur. Most common side effects over the long-term include hyperglycemia, 
hypertension, gastritis and gastrointestinal bleeding, osteoporosis, glaucoma,  cataracts, poor 
wound-healing, susceptibility to infection, weight gain, depression, psychosis and insomnia. 
Therapy with IVIg is usually better tolerated,  even if fever, flu like-syndrome and headache are 
not so uncommon. Serious adverse effects are rare and include tromboembolia, renal failure 
(mainly in patients with pre-existing renal failure), anaphylaxis (especially in patients with IgA 
deficiency) or aseptic meningitis. In the IMC trial [28] there were not significant differences in 
the proportion of patients experiencing adverse events even if slightly more adverse events were 
observed after steroids. The difference might become however more evident over the long period 
as shown in a retrospective study with a significantly higher proportion of patients experiencing 
adverse reaction after steroids (13%) than after IVIg (4%) [18]. A recent review of studies 
performed using daily or pulsed steroids showed however that pulsed monthly steroids are better 
tolerated than daily steroids with a consistent reduction in the frequency of most side effect [33].   
One of the major inconvenience of IVIg therapy in CIDP is the fact that most patients 
require regular IVIg infusions to prevent relapses with maintenance dosage and frequency of 
infusion ranging from 0.5 g/kg to 2 g/kg every two to 6 weeks. The inconvenience of repeated 
IVIg infusions in CIDP can be solved with home infusion of subcutaneous immunoglobulin 
(SCIg) whose efficacy as maintenance treatment was show to be similar to IVIg in a small 
controlled study on 15 patients [34].  The follow-up extension of this study also confirmed the 
prolonged efficacy of SCIg [35]. A more recent study assessing the long-term efficacy of SCIg in 
CIDP and MMN, showed however that up to one third of the patients with CIDP required an 
increased dosage of SCIg or preferred to return to IVIg [36]. This data seems to be confirmed by 
the preliminary and yet unpublished data of a recent controlled trials that confirmed that SCIg is 
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significantly more effective then placebo in preventing relapse within 6 months after suspending 
effective IVIg therapy even if one third of the patients relapsed within six months after passing 
from IVIg to SCIg [37]. This figure is higher than the 13% of relapse observed with IVIg over 
the same period in the extension phase of the ICE trial [13].  SCIg was recently shown to be 
similarly effective as IVIg as initial treatment in CIDP with only a modest delay in efficacy 
compared to IVIg [38]. The number of patients included in this study was however relatively 
small and the improvement in other parameters was quite marginal. SCIg remain a valid option 
for maintenance treatment in patients with CIDP reducing the inconvenience and cost of repeated 
hospital admission, when IVIg is not feasible at home, and the adverse events related to IVIg 
infusions. In addition, by performing the therapy at home patients do not loose time for their 
usual daily and working activities. Still the patients should be informed that up to one third of 
them may worsen when they pass from IVIg to SCIg. 
The cost of therapy with IVIg (and of SCIg) is consistently higher than that of steroids 
[39, 40]. In Italy for instance the yearly cost of IVIg varies, depending on the weight of the 
patient and the maintenance dose used, from 30,000 to 80,000 Euro while that of oral or 
intravenous steroids does not reach 1,000 Euro. This may explain which IVIg therapy might be 
difficult to propose in low-income countries.  
Plasma exchange. Even if considered as effective as IVIg or steroids in CIDP, plasma 
exchange is usually considered the third choice since it is more invasive for the patients and has 
a higher prevalence of side effects related to difficulty with venous access, use of citrate and 
hemodynamic changes [9].  In a retrospective study on 105 patients, a similar proportion of 
patients responded to plasma exchange (70%) or IVIg (64%) but more complications were 
observed after PE (10) than after IVIg (0) [41]. A similar difference in side-effects was observed 
in a retrospective study on 267 patients with CIDP treated with plasma exchange (19%), steroids 
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(12,5%) or IVIg (4%) [18]. Plasma exchange is rapidly effective as initial treatment in CIDP 
with improvement usually starting in a few days but the median time to deterioration after 
therapy discontinuation is relatively short with two-third of improved patients worsening within 
two weeks after stopping therapy [12]. These data together with the inconvenience related to the 
necessity of repeated admission for repeated exchanges makes of PE a less suitable option for the 
long–term treatment of CIDP [9]. It remains however a valid option for patients not responsive 
or becoming resistant to IVIg or steroids [18]. 
 Immune suppressive or immune modulator agents.  The necessity for long-term periodic 
treatments with IVIg or  PE, the serious adverse events associated with the chronic use of 
steroids and the not so uncommon development of resistance to these therapies led in the recent 
years to an extensive use of immune suppressive or immune modulators agents in CIDP [42]. 
None of these therapies was shown to be effective in randomized controlled trials. Azathioprine 
given in addition to oral prednisolone for 9 months did not permit to reduce the dose of steroids 
[43]. A randomized study with oral methotrexate in addition to IVIg or steroids [44] showed that 
the therapy was well tolerated but was not more effective than placebo in reducing the dose of 
steroids or IVIg necessary to maintain the improvement. Similar negative results were obtained 
in two trials with intramuscular interferon beta-1a  (IM IFNβ-1a) [45, 46] while a controlled trial 
with fingolimod was just interrupted after an interim analysis showing that the therapy was not 
effective [47].   
Despite the negative results from randomized studies, immunosuppressive are still 
frequently used in patients with CIDP. This derives from the results of  uncontrolled and often 
retrospective studies on small series of patients treated with other immune therapies including 
cyclosporine, interferon α, mycophenolate mofetil, etanercept or tacrolimus (reviewed in [42]).  
The necessity to confirm these preliminary reports in controlled studies derives from the results 
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of two controlled studies [44, 46] where 40% of the patients went into remission even under 
placebo. Not only a positive result may prompt the widespread use of a therapy whose efficacy 
might not be later confirmed, but also a negative data may block the use of a potentially useful 
therapy for several years. This might be the case of the lack of response in one patient to 
natalizumab [48] that was later reported to effective in three patients  [49]. Some additional 
caution should be used with the data on stem cell transplantation  [50] and alemtuzumab [51] 
whose efficacy in CIDP was often  associated with severe complications. The need for caution 
with immune suppressive therapies in CIDP  also derives from a retrospective study on 110 
patients with CIDP not adequately responsive to IVIg, steroids or plasma exchange, where the 
proportion of patients responding to different immune suppressive therapies ranged between 20-
30% while 10-20% of treated patients had adverse events related to the use of these therapies 
[52].   
The therapeutic decision might be difficult for severely disabled patients not responding 
to conventional therapies. It is generally assumed that this is related to the development of axonal 
loss even if this aspect has not been clearly demonstrated.  Few uncontrolled studies are 
consistent in showing that some disabled patients refractory to conventional therapies may 
respond to intravenous cyclophosphamide [53-55] while more recent studies showed the efficacy 
in some patients of rituximab [42] where  improvement was mainly associated with the presence 
of an haematological disease and particularly of  monoclonal gammopathy [56]. The possible 
beneficial effect of rituximab also derive from immunological studies showing that up to 10% of 
the  patients with CIDP have IgG4 antibodies to the proteins at the node of Ranvier Contactin 1 
or Neurofascin 155 [57-60]. These studies led to the opinion that in a minority patients the target 
for the immune response in CIDP may be the node and paranode (nodo-paranodopathy) affecting 
either axonal (such as contactin-1) or myelin (neurofascin-155) proteins. These patients were 
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also reported to share a poor response to IVIg while some of them improved with rituximab [61]. 
This was related to the fact that IgG4 antibodies do not activate complement, so that the possible 
inhibitory effect of IVIg on complement activation did not affect the action of these antibodies. 
Even if the number of patients is still small, this finding support the hypothesis that CIDP may 
include different immune mediated neuropathies affecting the myelin, the node or paranode with 
different pathogenesis and response to therapy [2].  
 Treatment of atypical CIDP. A variable proportion of patients presents with an atypical 
form of CIDP including Lewis-Sumner syndrome, distal acquired demyelinating symmetric 
(DADS) neuropathy, purely motor, purely sensory and focal CIDP [7]. The proportion of 
patients with  these atypical forms varies considerably in the literature from 1 to 50% [5, 7]. This 
might reflect the absence of definite diagnostic criteria for these atypical forms of CIDP and the 
fact that a variable proportion of patients with atypical CIDP at presentation eventually evolve 
into a typical CIDP.  This may also explain the heterogeneity in the response to the therapy in 
these patients. It is for instance accepted that patients with pure motor CIDP have poor response 
and possibly worsen under therapy with steroids even if these conclusion derives from very few 
studies [62-64]. There are also difference in the response to therapy in patients with Lewis 
Sumner syndromes with a proportion of patients responding to IVIg ranging in different studies 
from 38% [65] to 80% [66] compared to 80% of those with typical CIDP. In one of these studies 
there was also a poor response to plasma exchange (17%) compared to typical CIDP (81%)  [65].  
All these discrepancies leave it unclear whether these atypical forms of CIDP  are indeed 
variants of CIDP or whether they may represent different demyelinating neuropathies [2]. 
 
1.c How we treat CIDP 
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 We prefer to delay the treatment in patients with mild sensory deficits and minimal or no 
weakness that are not limited or consistently disturbed in their daily life explaining to the patient 
that spontaneous improvement may occasionally occur and that the possible adverse events or 
inconvenience related to therapy may be even more disturbing than mild neuropathy symptoms.  
In patients who do not improve, continue to worsen, or have motor and sensory deficits at 
presentation or are disturbed by their sensory symptoms, treatment with steroids or IVIg is first 
considered after discussing with the patients the pro and cons of each treatment. 
Contraindications to corticosteroids will influence the choice towards IVIg and vice versa. In 
patients with purely motor CIDP, we still consider IVIg as the first choice. If we need however 
to use corticosteroids,  we closely monitor patients for possible deterioration. Patients not 
responding to IVIg or steroids are shifted to the other therapy. We should however remember 
that steroids may become effective after several weeks and that over 50% of  the patients 
responsive to IVIg do so after the second course of IVIg. We prefer to reserve plasma exchange 
for patients not responsive to the other two therapies. 
For IVIg we start at the dose of 2 gm/kg body weight over 3-5 consecutive days.  The 
onset of action is rapid, and the side effect profile is rather benign. In a few patients, the effects 
of IVIg are sustained eliminating the need for additional treatment. When improvement is 
temporary, we give IVIg periodically starting with the dose of 1g/kg at a frequency sufficient to 
prevent the  wear-off effect of therapy. The dosage of IVIg is subsequently slowly reduced to 
achieve the minimal effective dose. We consider subcutaneous immunoglobulin a valid 
alternative for chronic therapy with immunoglobulins as far as they are given at the same (or 
even higher) monthly dose  IVIg. 
For steroids, we prefer to use monthly course of intravenous methylprednisolone at the 
starting dose of 2g over 2-4 consecutive days. Pulsed oral dexamethasone (40 mg for four days) 
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is a valid  alternative. This pulsed regimen can be also performed in patients with diabetes or 
glucose intolerance in whom we prefer to admit patients to better monitor and adjust glucose 
levels with insulin. Daily oral steroids can be also used at the standard daily dosage of 60 mg/day 
of prednisone even if this regimen may have more frequent adverse events than pulsed therapy. 
Patients should be educated regarding the side effects of steroids and instructed in the use of 
supplemental calcium and vitamin D, gastro protection and on the need for monitoring of blood 
pressure, glucose and electrolytes. After 2-3 months, the dose of steroid can be gradually reduced 
and eventually suspended after 6 months closely monitoring the possible worsening of the 
patients in which case the effective therapy is resumed. Daily oral steroids may be shifted to an 
alternate day regimen after 6-8 weeks that is better tolerated than the daily regimen.  
In patients non responsive or having contraindications to IVIg and steroids we perform 
plasma exchange (usually 4-5 courses of one plasma volume on alternate days). The onset of 
action generally is rapid. If the effect is sustained, no further treatment is required.  If 
improvement occurs but the patient relapses, plasma exchange is initially repeated after one or 
two weeks and subsequently delayed to a frequency of 1 course every 1-2 months.  
Due to lack of consistent evidence supporting the use of immune suppressive agents we 
reserve them to patients who remain disabled despite the above mentioned therapies or who have  
failed to respond to all of them, while we do not to use them to reduce the cost of therapy. In 
these patients we use intravenous cyclophosphamide a the monthly dose of 0.7-1g/m2 for six 
months. In patients with an associated monoclonal gammopathy or in those not improving after 
cyclophosphamide we use rituximab at the dose of 1 g repeated after two weeks. 
 
2. MULTIFOCAL MOTOR NEUROPATHY 
2.a Clinical features and diagnosis 
 15 
Multifocal motor neuropathy (MMN) is a purely motor mono neuritis multiplex 
characterized by the presence of multifocal partial conduction blocks (CB) on motor nerves [67, 
68] .The frequent association of MMN with antibodies to the ganglioside GM1 and the 
improvement observed in most patients after IVIg support the opinion that the disease is 
immunologically mediated. MMN is a rare neuropathy with a prevalence of  0.5-0.6 per 100,000 
inhabitants [67, 68]. MMN almost invariably presents with progressive, usually distal, 
asymmetric weakness in the upper limbs in the distribution of individual and usually not 
contiguous motor nerves [67, 68].  One of the typical feature of this neuropathy is the absence of 
sensory impairment even in the territory of affected sensorimotor nerve. Some patients may 
report mild sensory symptoms but only a minority of  them have a minor sensory loss. Most 
patients MMN carries an overall good prognosis quoad vitam, even if the majority of them 
become disabled in their daily life because of a reduced dexterity in manual activities, while few 
patients become disabled in walking [67]. 
 Diagnostic criteria for MMN have been proposed by several groups including the 
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM)[70] and the 
Joint Task force of the EFNS/PNS [71]. The diagnosis mainly relies on the presence of 
persistent, multifocal, partial CB  in motor nerves outside the usual sites of nerve compression.  
The diagnosis is also supported by the frequent occurrence of increased levels of serum IgM 
antibodies to the ganglioside GM1 with frequency in most laboratory of  40-50% [67]. These 
antibodies are not specific for this disease and can be also found in other immune neuropathies 
and in 5-10% of patients with MND even if  the majority of them have lower antibody levels 
than patients with MMN. Several attempts have been performed to improve the sensitivity of 
anti-GM1-antibodies in MMN using more sophisticated techniques or testing GM1 in addition to 
other glycolipids. The combination of GM1 with galactocerebroside increases the sensitivity of 
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GM1 testing in MMN of approximately 20% with a marginal reduction of the specificity and 
positive predictive value for MMN [72]. Magnetic resonance (MR) imaging studies of the 
forearm or brachial plexus  may show in some patients an asymmetrically increased signal 
intensity in T2 -weighted images or in T1-weighted images after gadolinium enhancement 
associated with diffuse nerve swelling of the brachial plexus [73]. Similarly promising results 
were observed with ultrasound study of the nerves [74]. 
 
2.b Treatment and management 
Almost 80% of patients with MMN respond to IVIg [75], whose efficacy has been 
confirmed in five randomized, double-blind, placebo-controlled trials on a total of 75 patients 
[76-80]. IVIg induces a rapid improvement which often occurs within one week of treatment and 
is usually more evident in recently affected regions with minor or no effect on stabilized deficits. 
Only a few patients have persistent improvement after a single or few courses of therapy while in 
most patients the effect of IVIg lasts a few weeks and has to be maintained with periodic IVIg 
infusions for long periods of time [81-84].  Maintenance therapy can be also performed with 
subcutaneous immunoglobulin (SCIg) whose efficacy as maintenance treatment has been 
confirmed in two small randomized controlled trials [86, 87]. A recent study assessing the long-
term efficacy of SCIg in MMN, showed however that almost 50% of the patients with MMN 
required an increased dosage of SCIg or preferred to return to IVIg [36]. 
A minority of patients with MMN do not respond or become resistant to IVIg while in 
others IVIg may be difficult to perform because of their elevated cost. Steroids and plasma 
exchange are ineffective in MMN and can be also associated with clinical worsening [67]. High-
dose intravenous cyclophosphamide, oral azathioprine and interferon −β1a (IFN- β1a) were also 
reported to be effective in some patients in open uncontrolled studies [88] while the only 
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randomized double blind controlled trial with immunosuppressant in MMN showed that 
mycophenolate mofetil did not permit to increase the effectiveness or to reduce the dose of IVIg 
[89]. More recent open trials showed that oral methotrexate [90] and eculizumab [91] were 
marginally effective in some patients but did not permit to consistently reduce the dose of  IVIg 
therapy. A positive effect was also reported with rituximab [89] even if the results were not  
subsequently confirmed [93]. A recent Cochrane review concluded that at the present time there 
is little evidence to support the use of any immunosuppressant in MMN [88], and confirmed that 
IVIg remains the gold standard for the treatment of MMN. 
 
2.c How we treat MMN 
In MMN we start with IVIg therapy at the standard dose of 2g/kg on 2-5 consecutive 
days followed by maintenance infusions ranging from 0.4g/kg once a week to 1-2g/kg every 2-5 
weeks. We frequently adjust however therapy in these patients since over time, several patients 
become progressively less responsive to IVIg and require increasing dosage (in case of 
insufficient response) or frequency (in case of reduced duration of the response) of IVIg to 
maintain improvement. SCIg is a valid alternative for maintenance treatment even if the dosage 
often needs to be increased over time. In the few patients not responding or becoming resistant to 
IVIg  we consider the use of  use intravenous cyclophosphamide a the monthly dose of 0.7-
1g/m2 for six months. 
 
3. NEUROPATHY ASSCIATED WITH IgM MONOCLONAL GAMMOPATHY AND 
ANTI-MAG ANTIBODIES 
3.a Clinical features and diagnosis 
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Almost 50% of patients with neuropathy associated with IgM monoclonal gammopathy 
have antibodies to the myelin-associated glycoprotein (MAG) [94, 95]. This is a rare neuropathy 
with an estimated prevalence of at least 20 per 100.000 in the population above 50 years [94].  
The majority of affected patients are men presenting their first neuropathy symptoms in the sixth 
or seventh decade. Almost 80% of them have IgM MGUS while most remaining patients have 
Waldenström’s macroglobulinemia (WM) that in these patients is frequently indolent.  
Most patients present with sensory symptoms in legs including distal paresthesias, hypo-
dysestesia, cramps or other pains and unsteadiness of gait. Weakness is frequently absent at 
onset. An intentional and postural tremor in the upper limbs is often reported being sometime 
quite disabling and in some patients it can be the presenting symptom. On neurological 
exhamination,  the neuropathy is characterized by a distal and symmetric, predominantly deep 
sensory involvement, gait ataxia and postural tremor in the upper limbs while motor impairment 
is usually less prominent and often appears later.  The majority of patients with anti-MAG 
antibodies have a relatively favourable long-term prognosis with 25-30% of them becoming at 
least moderately disabled after 10 year and 50% after 15 years [96, 97].  
 
3.b Treatment and management 
Several data support the possible pathogenetic role of anti-MAG IgM in the neuropathy 
[94] as also confirmed by the correlation of clinical improvement with the reduction of antibody 
titers. Almost 50% of reported patients improved, at least temporarily, after one of more immune 
therapies including steroids, plasmaexchange, a number of cytotoxic agents, IVIg, fludarabine, 
cladribine and interferon-α [96]. The efficacy of of these therapies has not been so far confirmed 
in randomised controlled trials most of whom showed at the most a marginal effect [98]. More 
recently a number of open pilot trials have suggested the efficacy in these patients of the 
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humanised monoclonal antibody rituximab directed against the CD20 antigen [99-102]. The 
efficacy of rituximab in anti-MAG neuropathy was also assessed in two controlled trials, one on 
26 patients [103] and the other on 54 patients [104]. Even if  neither trial met the pre-specified 
primary outcome measures, both studies showed a 20% to 30% absolute increase in the number 
of patients treated with rituximab improving in disability compared to those receiving placebo. A 
recent revision  combining the results of these two trials concluded that rituximab is beneficial in 
this neuropathy improving disability and  the subjective impression of change [98]. In 
responding patients the benefit was reported to last up to 2 years in 80% of the patients and 3 
years in 60% of them [105]. This aspect is important for the long term management of the 
patients and should be balanced with the side effects including the occasional development of 
progressive multifocal leucoencephalopathy [106]. Recent studies on small series of patients and 
the revision of a large series of french  patients reported on the possible additional efficacy of the 
association of rituximab with other therapy used in WM including fludarabine [107] and 
bendamustine [108]. These results should be however confirmed in controlled studies. Even if 
plasma exchange was not shown to be more effective than placebo when given in addition to 
immune therapies, it may be useful in some patients with a rapidly progressive course [109].     
Some caution in the interpretation of these results derives however from the fact that 
variable levels of anti-MAG antibodies were considered to be diagnostic for this neuropathy. In 
our laboratory for instance antibodies lower that 1/6,400 by western blot assay with purified 
human myelin were no strictly associated with this neuropathy [110]. A more recent 
commercially available ELISA system considered abnormal values above 1,000 Bühlmann titer. 
Even if this system has the advantage to avoid the cumbersome procedure of  home-made assays, 
it carries the risk of including a more heterogeneous group of patients [110] highlighting the 
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necessity to better define cut-off levels for the definition of this neuropathy based on adequately 
large control population.  
 
3.b How we treat neuropathy associated with anti-MAG antibodies 
We curently use symptomatic therapies for tremor and paresthesias in symptomatic 
patients with neuropathy asssociated with anti-MAG antibodies who are not impaired in daily 
acivities and reassure them on the usually favourable functional prognosis for several years. In 
patients impaired in their daily-life or who have evidence of an unusually rapid progression we 
consider  rituximab as the first option at the dose of 375mg/m2 every weeks for four weeks. We 
eventually repeat this dose after six months if the first course did not stop the progression of 
symptoms especially if there is an insufficinet reduction of B-cell counts while in patients 
stabilized or improved we consider an extra infusion after 6 and 12 months to prevent a rebound 
of B-cells. We occasionally propose a course of plasma exchange in patients with an unusal rapid 
progression of the neuropathy to reduce the progression of the neuropathy or in patients not 
responding to rituximab. 
 
CONCLUSION 
In the last twenty years several studies have permitted to demonstrate the efficacy of a 
number of immune therapies in immune mediated neuropathies and to confirm that these 
neuropathies, even if  all characterized by a pathological process involving nerve myelin or the 
node of Ranvier,  are separate clinical entities with different responses to therapies. Even within 
CIDP, the possibility that this is not a disease with different clinical presentation but a syndrome 
including different clinical entities with different pathogenesis and response to therapies is 
currently extensively investigated.   
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From all these studies it also appear that beside the efficacy of IVIg, steroids and PE in 
CIDP, IVIg in MMN and possibly rituximab in neuropathy associated with anti-MAG 
antibodies, there is inconsistent evidence from controlled studies that the other immune therapies 
currently used to reduce the frequency of IVIg or PE or the adverse events frequently associated 
with the chronic use of steroids, may have efficacy in these neuropathies. In addition most of 
these studies showed that a similar proportion of patients treated with these therapies worsen 
after the suspenison of the effective therapy compared to patients treated with placebo. This fact 
highlight the need for controlled studies in these neuropathies to ensure that the frequently 
reported improvement in uncontrolled studies reflect their real efficay and not a sponatenaous 
stabilization or remission of the disease.   
 
Expert commentary  
Ther are still unanswered problems in the treatment of these neuropathies. In CIDP it is  
unclear whether  the more prolonged efficay of steroids may balance the higher cost and better 
tolerability of IVIg. It is also unclear whether the suggested combined inital use of IVIg  and 
pulsed steroids  may unify the advantage of the more rapid efficay of IVIg with the prolonged 
effiacy of steroids. A new randomized controlled trial comparing the efficacy of IVIg with that 
of IVIg combined with steroids is under consideration. Despite their widespraed use, there is no 
data from ramdomized controlled trial supporting the efficay of immune suppressive therapy in 
CIDP. I think that particular attention should be given to the newly developed monoclonal 
antibodies including ocrelizumab, alemtuzumab and natalizumab that were shown to be effective 
in patients with multiple sclerosis (MS), even if the results obtained in immune mediated 
neuropathies with therapies effective in MS have been so far quite disappointing. Further studies 
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on the possible pathogenetic mechanism of CIDP are also needed to clarify whetere the presence 
of different antibody reactivities in these patients may reflect the presence of different clinical 
entities and whether these may have different response to therapies.   
Things are possibly more simple in MMN where there is not much choice in the initial 
treatment of the disease. Most stsudies are now addressing the possible benefit in these patients 
(as in those with CIDP) of the use of SCIg as maintenace treatment. This will not really change 
the therapeutical strategy in these patients but might solve some of the incovenience related to 
the need of chronic IVIg infusions. It remain however unclear why in this disease, despite the 
considerable evidence supporting an autoimmune pathogenesis, other immune therapies 
including plasma exchane and steroids are not effective and may even worsen the disease. A 
similar lack of evidence of the effiacy of any other immune therapies in MMN also support the 
need to better understand what is the effective pathogenesis of MMN and whether there are other 
possible mechamisms of action of IVIg that might reveal a possible non immune mediated action 
of this therapy in MMN. 
Even if several data suppot the hypothesis that anti-MAG antibodies have a role in 
causing the neuropathy, this neuropathy does not really represent a typical autoimmune disease 
considering the slowly progressive course of the disease, the absence of  temporal variability in 
antibody leves and their constant monoclonality. This is why most of the therapies used in this 
neuropathy are those used in hematological malignacy with sparse data on  their long-term 
efficay and safety. Most studies in patients with anti-MAG neuropathy report indeed the effiacy 
of  these therapies for no more than two years while the disease lasts in most patients several 
years. Better data are therfore needed to clarify what would be the best regimen and therapy to be 




The widespread interest in these immune neuropathies derives form the fact that these are 
among the  best treatable chronic neuropathies. This has led to the performance of several 
controlled studies in this field in the last twenty years. Despite the demonstration in a few studies 
of the efficay of IVIg in CIDP and MMN, regular authorities have so far decided that not all 
brands of IVIg should be registerd for their use in these neuropathies unless their proven efficacy 
even if  recent observational data support their similar efficacy in these neuropathies [110]. This 
has led to a number of registrative studies with different brand of IVIg and possibly of SCIg 
diverting the attention of clinicians to these usually remunerative studies. This also because 
studies with other expensive therapies might be difficult without the support of producing 
companies that have a limited interested in these rare neuropathies. All this risks to slow in the 
next few years the study of new therapies in these neuropathies leaving the patients dependent on 
the chronic use of immunoglobulin with the only possible choice between their intravenous or 





• Chronic inflammatory neuropathies are an heterogeneous group of rare disorders caused by 
an autoimmune reaction against peripheral nerve. Several studies have shown the efficacy of  
immune therapies in these neuropathies and confirm that these neuropathies, even if  all 
characterized by a pathological process involving nerve myelin or the node of Ranvier, are 
separate clinical entities with different responses to therapies.  
• IVIg are more frequently or rapidly effective than steroids in CIDP even if steroids, when 
effective, are less frequently associated with deterioration after therapy discontinuation. PE is 
also effective in CIDP but it is less used as it is more invasive and has more side effects. 
SCIg are effective as maintenance therapy in CIDP while the efficacy of immune suppressive 
therapies has not been so far confirmed in controlled studies.  
• IVIg remain the only therapy of proven efficacy in MMN. Its efficacy needs however to be 
maintained with periodic IVIg infusions or with SCIg.  There are no data from controlled 
studies supporting the efficacy of immune suppressive therapies in MMN. 
•  Recent controlled studies have shown that rituximab its effective in neuropathy associated 
with anti-MAG antibodies even if its efficacy and safety over the long-term are still 
unsettled. A better definition of cut-off levels for antibody levels in this neuropathy should be 
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